会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明申请
    • Intracardiac impedance and its applications
    • 心内阻抗及其应用
    • US20070043394A1
    • 2007-02-22
    • US11208922
    • 2005-08-22
    • Yunlong ZhangJames GilkersonYongxing ZhangBoyce Moon
    • Yunlong ZhangJames GilkersonYongxing ZhangBoyce Moon
    • A61N1/39
    • A61N1/3962A61N1/3621A61N1/36521A61N1/3925
    • A system to measure intracardiac impedance includes implantable electrodes and a medical device. The electrodes sense electrical signals of a heart of a subject. The medical device includes a cardiac signal sensing circuit coupled to the implantable electrodes, an impedance measurement circuit coupled to the same or different implantable electrodes, and a controller circuit coupled to the cardiac signal sensing circuit and the impedance measurement circuit. The cardiac signal sensing circuit provides a sensed cardiac signal. The impedance measurement circuit senses intracardiac impedance between the electrodes to obtain an intracardiac impedance signal. The controller circuit determines cardiac cycles of the subject using the sensed cardiac signal, and detects tachyarrhythmia using cardiac-cycle to cardiac-cycle changes in a plurality of intracardiac impedance parameters obtained from the intracardiac impedance signal.
    • 测量心内阻抗的系统包括可植入电极和医疗装置。 电极感测受试者心脏的电信号。 医疗装置包括耦合到可植入电极的心脏信号感测电路,耦合到相同或不同可植入电极的阻抗测量电路,以及耦合到心脏信号感测电路和阻抗测量电路的控制器电路。 心脏信号感测电路提供感测的心脏信号。 阻抗测量电路感测电极之间的心内阻抗,以获得心内阻抗信号。 控制器电路使用感测到的心脏信号来确定受试者的心脏周期,并且使用从心脏内阻抗信号获得的多个心内阻抗参数中的心脏周期与心脏周期变化来检测快速性心律失常。
    • 9. 发明申请
    • Atrial antitachycardia pacing management
    • 心房抗心动过速起搏管理
    • US20050096708A1
    • 2005-05-05
    • US10698858
    • 2003-10-31
    • Gary SeimJames Gilkerson
    • Gary SeimJames Gilkerson
    • A61N1/08A61N1/362A61N1/37
    • A61N1/37A61N1/3621A61N1/371A61N2001/083
    • A system and method provides for managing atrial ATP therapy in response to possible atrial lead dislodgment. An impedance of an atrial lead is measured for a particular patient. The measured impedance is compared with an impedance threshold developed for the particular patient. Atrial ATP therapy delivery is disabled in response to the measured impedance deviating from the impedance threshold by a predetermined factor. The impedance threshold may be developed from one or more atrial lead impedance measurements, and may also be characterized by a mean or a median of several atrial lead impedance measurements. The predetermined factor may be characterized by a percentage change, a fixed delta change, or both a percentage change and a fixed delta change in the measured impedance relative to the impedance threshold.
    • 一种系统和方法提供用于管理心房ATP治疗以响应可能的心房前叉移位。 针对特定患者测量心房线的阻抗。 将测量的阻抗与为特定患者开发的阻抗阈值进行比较。 响应于从阻抗阈值偏离预定因子的测量阻抗来禁用心房ATP治疗递送。 阻抗阈值可以从一个或多个心房导联阻抗测量开发,并且还可以通过几个心房导联阻抗测量的平均值或中值来表征。 预定因子可以通过百分比变化,固定的δ变化或者测量的阻抗相对于阻抗阈值的百分比变化和固定的增量变化来表征。